Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS.
Xu B, et al. Among authors: dai ms.
Nat Med. 2024 Oct 1. doi: 10.1038/s41591-024-03269-z. Online ahead of print.
Nat Med. 2024.
PMID: 39354196